HCPCS Level II code Q5115 denotes the biosimilar rituximab product Truxima, billed per 10 mg unit for parenteral administration. This biologic agent is used across multiple specialty settings for immune-mediated diseases and oncology indications where rituximab is indicated. Nationally, clear coding for biosimilars like Q5115 matters for accurate drug identification, payment processing, inventory tracking, and biosimilar adoption monitoring.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for Q5115, typical sites of service, and which stakeholders commonly encounter this code. The publication also outlines what to expect in benchmarking and policy coverage discussions: payment benchmarks for biosimilar rituximab, coding guidance considerations, and payer coverage patterns.

This summary prepares clinicians, coding professionals, and policy analysts to understand where Q5115 fits in drug billing workflows, what services it represents, and which major payers are relevant for coverage and reimbursement conversations. Data not available in the input is noted where applicable.